Literature DB >> 36264865

Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.

Kenichi Mochizuki1,2, Shin-Ei Kudo1, Kazuki Kato1,2, Koki Kudo1, Yushi Ogawa1, Yuta Kouyama1, Yuki Takashina1, Katsuro Ichimasa1,3, Taro Tobo4, Takeo Toshima2, Yuichi Hisamatsu2, Yusuke Yonemura2, Takaaki Masuda2, Hideyuki Miyachi1, Fumio Ishida1, Tetsuo Nemoto5, Koshi Mimori2.   

Abstract

BACKGROUND: Colorectal cancer (CRC) can be classified into four consensus molecular subtypes (CMS) according to genomic aberrations and gene expression profiles. CMS is expected to be useful in predicting prognosis and selecting chemotherapy regimens. However, there are still no reports on the relationship between the morphology and CMS.
METHODS: This retrospective study included 55 subjects with T2 CRC undergoing surgical resection, of whom 30 had the depressed type and 25 the protruded type. In the classification of the CMS, we first defined cases with deficient mismatch repair as CMS1. And then, CMS2/3 and CMS4 were classified using an online classifier developed by Trinh et al. The staining intensity of CDX2, HTR2B, FRMD6, ZEB1, and KER and the percentage contents of CDX2, FRMD6, and KER are input into the classifier to obtain automatic output classifying the specimen as CMS2/3 or CMS4.
RESULTS: According to the results yielded by the online classifier, of the 30 depressed-type cases, 15 (50%) were classified as CMS2/3 and 15 (50%) as CMS4. Of the 25 protruded-type cases, 3 (12%) were classified as CMS1 and 22 (88%) as CMS2/3. All of the T2 CRCs classified as CMS4 were depressed CRCs. More malignant pathological findings such as lymphatic invasion were associated with the depressed rather than protruded T2 CRC cases.
CONCLUSIONS: Depressed-type T2 CRC had a significant association with CMS4, showing more malignant pathological findings such as lymphatic invasion than the protruded-type, which could explain the reported association between CMS4 CRC and poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36264865      PMCID: PMC9584453          DOI: 10.1371/journal.pone.0273566

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


  29 in total

Review 1.  Keratin expression in human tissues and neoplasms.

Authors:  P G Chu; L M Weiss
Journal:  Histopathology       Date:  2002-05       Impact factor: 5.087

2.  Clinical outcomes and factors related to resectability and curability of EMR for early colorectal cancer.

Authors:  Jae Jun Park; Jae Hee Cheon; Ji Eun Kwon; Jae Kook Shin; Soung Min Jeon; Hyun Jung Bok; Jin Ha Lee; Chang Mo Moon; Sung Pil Hong; Tae Il Kim; Hoguen Kim; Won Ho Kim
Journal:  Gastrointest Endosc       Date:  2011-12       Impact factor: 9.427

3.  Risk factors of recurrence in T1 colorectal cancers treated by endoscopic resection alone or surgical resection with lymph node dissection.

Authors:  Yuta Kouyama; Shin-Ei Kudo; Hideyuki Miyachi; Katsuro Ichimasa; Shingo Matsudaira; Masashi Misawa; Yuichi Mori; Toyoki Kudo; Takemasa Hayashi; Kunihiko Wakamura; Fumio Ishida; Shigeharu Hamatani
Journal:  Int J Colorectal Dis       Date:  2018-05-11       Impact factor: 2.571

Review 4.  Current problems and perspectives of pathological risk factors for lymph node metastasis in T1 colorectal cancer: Systematic review.

Authors:  Katsuro Ichimasa; Shin-Ei Kudo; Hideyuki Miyachi; Yuta Kouyama; Kenichi Mochizuki; Yuki Takashina; Yasuharu Maeda; Yuichi Mori; Toyoki Kudo; Yuki Miyata; Yoshika Akimoto; Yuki Kataoka; Takafumi Kubota; Tetsuo Nemoto; Fumio Ishida; Masashi Misawa
Journal:  Dig Endosc       Date:  2022-01-11       Impact factor: 7.559

5.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.

Authors:  Yojiro Hashiguchi; Kei Muro; Yutaka Saito; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Kiyoshi Hasegawa; Kinichi Hotta; Hideyuki Ishida; Megumi Ishiguro; Soichiro Ishihara; Yukihide Kanemitsu; Yusuke Kinugasa; Keiko Murofushi; Takako Eguchi Nakajima; Shiro Oka; Toshiaki Tanaka; Hiroya Taniguchi; Akihito Tsuji; Keisuke Uehara; Hideki Ueno; Takeharu Yamanaka; Kentaro Yamazaki; Masahiro Yoshida; Takayuki Yoshino; Michio Itabashi; Kentaro Sakamaki; Keiji Sano; Yasuhiro Shimada; Shinji Tanaka; Hiroyuki Uetake; Shigeki Yamaguchi; Naohiko Yamaguchi; Hirotoshi Kobayashi; Keiji Matsuda; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2019-06-15       Impact factor: 3.402

6.  CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and β-catenin stabilisation via transactivation of PTEN expression.

Authors:  Junhui Yu; Shan Li; Zhengshui Xu; Jing Guo; Xiaopeng Li; Yunhua Wu; Jianbao Zheng; Xuejun Sun
Journal:  Br J Cancer       Date:  2020-11-26       Impact factor: 7.640

7.  Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.

Authors:  Yaqi Li; Qianlan Yao; Long Zhang; Shaobo Mo; Sanjun Cai; Dan Huang; Junjie Peng
Journal:  Oncologist       Date:  2020-09-28

8.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

9.  Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer.

Authors:  Akira Okita; Shin Takahashi; Kota Ouchi; Masahiro Inoue; Mika Watanabe; Mareyuki Endo; Hiroshi Honda; Yasuhide Yamada; Chikashi Ishioka
Journal:  Oncotarget       Date:  2018-04-10

10.  The role of CDX2 in renal tubular lesions during diabetic kidney disease.

Authors:  Huiming Liu; Rui Yan; Luqun Liang; Huifang Zhang; Jiayi Xiang; Lingling Liu; Xiaohuan Zhang; Yanwen Mao; Wei Peng; Ying Xiao; Fan Zhang; Yuxia Zhou; Mingjun Shi; Yuanyuan Wang; Bing Guo
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.